[Pharmacokinetics of radioactively labeled glisoxepide in the animal].
D000818:Animals; D001381:Azepines / Q000378:metabolism*; D001646:Bile / Q000378:metabolism; D002250:Carbon Radioisotopes; D003201:Computers; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005243:Feces / Q000032:analysis; D005260:Female; D006207:Half-Life; D000882:Haplorhini; D007004:Hypoglycemic Agents / Q000378:metabolism*; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D008297:Male; D010080:Oxazoles / Q000378:metabolism*; D010179:Pancreas / Q000378:metabolism; D010215:Papio; D011817:Rabbits; D051381:Rats; D013045:Species Specificity; D013453:Sulfonylurea Compounds / Q000378:metabolism*; D013462:Sulfur Radioisotopes; D013997:Time Factors; D014316:Tritium
D001381:Azepines; D002250:Carbon Radioisotopes; D007004:Hypoglycemic Agents; D010080:Oxazoles; D013453:Sulfonylurea Compounds; D013462:Sulfur Radioisotopes; D014316:Tritium
Pharmakokinetik von radioaktiv markiertem Glisoxepid beim Tier